SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1957-01-01
- Employees
- 1.3K
- Market Cap
- -
- Website
- http://www.snbl.co.jp
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Phase 2
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT00787566
- Locations
- 🇺🇸
The study is conducted at 14 Centers, in 14 cities accross the United States, The study is managed by Kendle International, in Wilmington, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath